COVID-19

This study evaluate the change in preoperative anxiety, baseline (M1) and pre-induction anxiety levels (M3), as shown by children undergoing MAS determined by the m-YPAS scale in the different APO management groups.Patients will be allocated in one of this four groups: hydroxyzine+clown; hydroxyzine alone, clowns alone or nothing

Inclusion Criteria:

• Children between 2 and 16 years old
• Patients with programmed major ambulatory surgery.
• Assessment of anesthetic risk ASA I-II.
• Informed consent signed by their legal authorized representatives.
• No antihistaminic allergies.
• Assent signed by children between 12 and 16 years old.

Exclusion Criteria:

• Patients with previous surgeries.
• Anesthetic risk ASA more than II.
• Patients with hypersensitivity to the active substance, to any of the excipients, to cetirizine, to other piperazine derivatives, to aminophylline or etilenamida
• Patients with porphyria
• Patients with known QT prolongation, either congenital or acquired
• Patients with known risk factors for QT prolongation including a pre-existing cardiovascular disease, previous electrolyte imbalances, family history of sudden cardiac death, significant bradycardia and concomitant use of drugs with potential known to produce QT prolongation and / or induce Torsades de Pointes.

Clowns: outcomes assesor Hidroxicine: participant, care provider, investigator and outcomes assessor